Pierre Naibo

Pierre Naibo currently serves as the Clinical Sciences Director within the Medical team at SOPHiA GENETICS, where he plays a pivotal role in advancing the company's mission to democratize genomic medicine. Leveraging his extensive background as a medical geneticist, Pierre brings a deep understanding of germline and somatic genomics, honed through years of experience working in cancer research centers in France, with a focus on NGS, WGS, WES, and RNA sequencing platforms such as AURAGEN. His expertise spans molecular biology, clinical research, and biotechnologies, enabling him to bridge the gap between cutting-edge genomic data and clinical application.

In his current role, Pierre oversees the development and refinement of SOPHiA GENETICS' platform tools, including the actionability knowledge base for somatic analysis, reporting modules for both somatic and germline variants, and longitudinal tracking capabilities for minimal residual disease (MRD), disease monitoring, and graft surveillance. His responsibilities encompass ensuring seamless integration of these modules into an end-to-end workflow, facilitating accurate and actionable genomic interpretation, and maintaining the platform’s competitive edge through strategic analysis and product vision.

Pierre’s expertise in molecular biology techniques such as RT-PCR, Sanger sequencing, MLPA, and NGS, combined with his clinical research background, enables him to guide the platform’s development with a focus on clinical utility and precision medicine. His leadership ensures that SOPHiA GENETICS’ solutions effectively support clinicians and researchers in delivering data-driven, personalized treatment strategies, ultimately contributing to improved patient outcomes in oncology and beyond.